Abstract
Obesity and obesity-related disorders have dramatically increased globally in the last decades. These entities are commonly associated with a state of insulin resistance and the relationship between extensive lipid deposition and insulin resistance is widely accepted. The underlying mechanisms for insulin resistance, however, are still incompletely understood. Evidence from experimental research and human studies in the last years has suggested that innate immune pathways and inflammatory mechanisms also might play a role. Insulin resistance in case of obesity is commonly accompanied by low-grade systemic inflammation and adipose tissue inflammation. The expression of various pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1 and IL-6 is increased in adipose tissue and its expression linked to systemic inflammation and accompanying insulin resistance. Weight loss reduces this enhanced cytokine expression in the adipose tissue and thereby improves systemic inflammation. Whereas there is also substantial evidence that pro-inflammatory cytokines, certain members of the inflammasome and various transcription factors such as nuclear factor-κB play a major role in animal models of insulin resistance and type 2 diabetes, human studies neutralizing certain pro-inflammatory cytokines suggest so far that not all pro-inflammatory cytokines are of equal clinical importance. First clinical studies favor an important role for IL-1 family members and probably IL-6 but not for TNF-α in insulin-resistant states. Although we still have missing links in the understanding of insulin resistance, certain inflammatory pathways have also evolved in humans as central players.
Similar content being viewed by others
References
Aguirre V, Uchida T, Yenush L et al (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275:9047–9054
Arkan MC, Hevener AL, Greten FR et al (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191–198
Barbuio R, Milanski M, Bertolo MB et al (2007) Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 194:539–550
Bernstein LE, Berry J, Kim S et al (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166:902–908
Cai D, Yuan M, Frantz DF et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183–190
Carstensen M, Herder C, Kivimaki M et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: whitehall II prospective cohort study. Diabetes 59:1222–1227
Clowes GH Jr, Martin H, Walji S et al (1978) Blood insulin responses to blood glucose levels in high output sepsis and septic shock. Am J Surg 135:577–583
da Silva BS, Bonfa E, de Moraes JC et al (2010) Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals 38:567–569
Dandona P, Weinstock R, Thusu K et al (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907–2910
Di Gregorio GB, Hensley L, Lu T et al (2004) Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287:E182–E187
Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732
Dominguez H, Storgaard H, Rask-Madsen C et al (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42:517–525
Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107
Ebstein W (1876) Zur therapie des diabetes mellitus, insbesondere über die anwendeng der salicylauren natron bei demselben. Berliner Klinische Wochenschrift 13:337–340
Ehses JA, Lacraz G, Giroix MH et al (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 106:13998–14003
Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481–1489
Ferraz-Amaro I, Arce-Franco M, Muniz J et al (2011) Systemic blockade of TNF-α does not improve insulin resistance in humans. Horm Metab Res 43:801–808
Fu S, Watkins SM, Hotamisligil GS (2012) The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab 15:623–634
Glass CK, Olefsky JM (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15:635–645
Goldfine AB, Fonseca V, Jablonski KA et al (2010) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346–357
Goldfine AB, Buck S, Jablonski KA et al (2012) Targeting inflammation using SALsalate in patients with type 2 diabetes: effects on flow-mediated dilatation (TINSAL-FMD). Diabetes 61(Suppl 1):A303
Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83–86
Hak AE, Stehouwer CD, Bots ML et al (1999) Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19:1986–1991
He J, Usui I, Ishizuka K et al (2006) Interleukin-1 alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol 20:114–124
Hingorani AD, Casas JP (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379:1214–1224
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91
Hotamisligil GS, Peraldi P, Budavari A et al (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668
Hundal RS, Petersen KF, Mayerson AB et al (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321–1326
Kamari Y, Shaish A, Vax E et al (2011) Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol 55:1086–1094
Kanda H, Tateya S, Tamori Y et al (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494–1505
Kern PA, Saghizadeh M, Ong JM et al (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111–2119
Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417–3427
Kopp HP, Kopp CW, Festa A et al (2003) Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23:1042–1047
Koutroubakis IE, Oustamanolakis P, Malliaraki N et al (2009) Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 21:283–288
Lagathu C, Yvan-Charvet L, Bastard JP et al (2006) Long-term treatment with interleukin-1 beta induces insulin resistance in murine and human adipocytes. Diabetologia 49:2162–2173
Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526
Larsen CM, Faulenbach M, Vaag A et al (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663–1668
Li Z, Yang S, Lin H et al (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343–350
Mehta NN, McGillicuddy FC, Anderson PD et al (2010) Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 59:172–181
Meier CA, Bobbioni E, Gabay C et al (2002) IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 87:1184–1188
Miura K, Kodama Y, Inokuchi S et al (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139(323–334):e7
Moschen AR, Molnar C, Geiger S et al (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259–1264
Moschen AR, Molnar C, Enrich B et al (2011) Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med 17:840–845
Nold MF, Nold-Petry CA, Zepp JA et al (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014–1022
Ofei F, Hurel S, Newkirk J et al (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885
Ogata A, Morishima A, Hirano T et al (2011) Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 70:1164–1165
Owyang AM, Maedler K, Gross L et al (2010) XOMA 052, an anti-IL-1beta monoclonal antibody, improves glucose control and beta-cell function in the diet-induced obesity mouse model. Endocrinology 151:2515–2527
Paquot N, Castillo MJ, Lefebvre PJ et al (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316–1319
Pihlajamaki J, Kuulasmaa T, Kaminska D et al (2012) Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol 56:663–670
Pradhan AD, Cook NR, Manson JE et al (2009) A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care 32:3–8
Raymond RM, Harkema JM, Emerson TE Jr (1981) In vivo skeletal muscle insulin resistance during E. coli endotoxin shock in the dog. Circ Shock 8:425–433
Ridker PM, Thuren T, Zalewski A et al (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162:597–605
Rosenvinge A, Krogh-Madsen R, Baslund B et al (2007) Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 36:91–96
Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148:852–871
Schultz O, Oberhauser F, Saech J et al (2010) Effects of inhibition of interleukin-6 signaling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 5:e14328
Stienstra R, Tack CJ, Kanneganti TD et al (2012) The inflammasome puts obesity in the danger zone. Cell Metab 15:10–18
Svenson KL, Lundqvist G, Wide L et al (1987) Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 36:940–943
Uysal KT, Wiesbrock SM, Marino MW et al (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610–614
Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79
Wascher TC, Lindeman JH, Sourij H et al (2011) Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in “healthy” men with metabolic syndrome. Mol Med 17:189–193
Weisberg SP, McCann D, Desai M et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808
Weisberg SP, Hunter D, Huber R et al (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115–124
Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77–80
Yuan M, Konstantopoulos N, Lee J et al (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673–1677
Yudkin JS, Stehouwer CD, Emeis JJ et al (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978
Acknowledgments
This work was supported by the Christian Doppler Society.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Wieser, V., Moschen, A.R. & Tilg, H. Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective. Arch. Immunol. Ther. Exp. 61, 119–125 (2013). https://doi.org/10.1007/s00005-012-0210-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-012-0210-1